160833-27-2

Upstream product

• 288-32-4 1H-imidazole 
• 873-62-1 m-cyanophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1400660-71-0 (S)-2-{[2-tert-butyl-5-(3-hydroxybenzylcarbamoyl)thiophen-2-carbonyl]amino}-3-[(thiophene-2-carbonyl)amino]propionic acid 
• 1400663-11-7 C₂₇H₂₇N₃O₈S 
• 1400663-10-6 C₂₆H₂₅N₅O₆S 
• 1400663-09-3 C₂₃H₂₃N₅O₇S 
• 1400663-08-2 C₂₆H₂₅N₅O₆S 
• 1400663-07-1 C₂₅H₂₇N₅O₈S 
• 1400663-06-0 C₂₆H₂₅N₅O₆S 
• 1400663-05-9 C₂₃H₂₃N₅O₆S 
• 1400663-04-8 C₂₅H₂₅N₃O₇S 
• 1400663-03-7 C₂₃H₂₃N₅O₈S 
• 1400663-02-6 C₂₅H₂₅N₃O₈S 
• 1400662-97-6 C₂₆H₂₉N₃O₆S₂ 
• 1400662-96-5 C₂₃H₂₃N₃O₆S₂ 
• 1400660-85-6 (S)-3-[(benzoic acid-3-carbonyl)amino]-2-{[5-(3-hydroxybenzylcarbamoyl)-3-methylthiophene-2-carbonyl]amino}propionic acid 

Relevant academic research and scientific papers

COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

THIAZOLE AND THIOPHENE COMPOUNDS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD

AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE

A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R 5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.

Dehydroamino acids

Compounds of formula 1 and 1-1, wherein R1 is hydrogen, hydroxy, amino or halogen, R2 is hydrogen, hydroxy, or halogen and R3 is hydrogen (Formula 1) or R1 is hydrogen and R2 and R3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is R4 R5 are hydrogen, methyl, ethyl or halogen except that R4 r5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is where R6 R7 R8 and R9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is where R10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is where X and Y are independently methylene or nitrogen; or 5) B is where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.

Diaminopropionic acid derivatives

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

CYCLOALKANE DERIVATIVES

The invention concerns cycloalkane derivatives of the formula I wherein Ar1 is phenyl, naphthyl or a 10-membered bicyclic heterocyclic moiety which may optionally bear up to four substituents; A1 is a direct link to X1 or is (1-3C)alkylene; X1 is oxy, thi